Single Strain

HA-196

JUMP TO:
01
Summary

In one randomized, double-blind, placebo-controlled study, researchers evaluated the effectiveness of two probiotics, Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum), in alleviating gastrointestinal (GI) and psychological symptoms in adults with varying subtypes of IBS.1 Although the study suggested potential benefits for specific IBS subtypes, we have decided to exclude it from our database due to several concerns.

 

First, the quality of reporting in the study was inconsistent, with notable discrepancies in attrition values between the manuscript and a study table. Additionally, many results were either omitted or presented in illegible graphs. Furthermore, there were signs of result manipulation, and the involvement of the probiotic producer in revising the manuscript raises questions about the study’s impartiality.

Because of these issues, we can’t fully trust the findings. Consequently, we have disqualified both the study and the probiotics evaluated until higher-quality studies are conducted on these strains.

Key Takeaway:

The study on Lactobacillus paracasei HA-196 has been excluded from our database due to concerns about evidence quality. 

Dosing Recommendation

None

 

 

References:

  1. Lewis ED, Antony JM, Crowley DC, et al. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0165 in alleviating symptoms of irritable bowel syndrome(IBS): A randomized, placebo-controlled study. Nutrients 2020;12:1159. [doi: 10.3390/nu12041159].
Read More…

In one randomized, double-blind, placebo-controlled study, researchers evaluated the effectiveness of two probiotics, Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum), in alleviating gastrointestinal (GI) and psychological symptoms in adults with varying subtypes of IBS.1 Although the study suggested potential benefits for specific IBS subtypes, we have decided to exclude it from our database due to several concerns.

 

First, the quality of reporting in the study was inconsistent, with notable discrepancies in attrition values between the manuscript and a study table. Additionally, many results were either omitted or presented in illegible graphs. Furthermore, there were signs of result manipulation, and the involvement of the probiotic producer in revising the manuscript raises questions about the study’s impartiality.

Because of these issues, we can’t fully trust the findings. Consequently, we have disqualified both the study and the probiotics evaluated until higher-quality studies are conducted on these strains.

Key Takeaway:

The study on Lactobacillus paracasei HA-196 has been excluded from our database due to concerns about evidence quality. 

Dosing Recommendation

None

 

 

References:

  1. Lewis ED, Antony JM, Crowley DC, et al. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0165 in alleviating symptoms of irritable bowel syndrome(IBS): A randomized, placebo-controlled study. Nutrients 2020;12:1159. [doi: 10.3390/nu12041159].
Read More…
Find a probiotic with HA-196

There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this strain/blend.

In one randomized, double-blind, placebo-controlled study, researchers evaluated the effectiveness of two probiotics, Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum), in alleviating gastrointestinal (GI) and psychological symptoms in adults with varying subtypes of IBS.1 Although the study suggested potential benefits for specific IBS subtypes, we have decided to exclude it from our database due to several concerns.

 

First, the quality of reporting in the study was inconsistent, with notable discrepancies in attrition values between the manuscript and a study table. Additionally, many results were either omitted or presented in illegible graphs. Furthermore, there were signs of result manipulation, and the involvement of the probiotic producer in revising the manuscript raises questions about the study’s impartiality.

Because of these issues, we can’t fully trust the findings. Consequently, we have disqualified both the study and the probiotics evaluated until higher-quality studies are conducted on these strains.

Key Takeaway:

The study on Lactobacillus paracasei HA-196 has been excluded from our database due to concerns about evidence quality. 

Dosing Recommendation

None

 

 

References:

  1. Lewis ED, Antony JM, Crowley DC, et al. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0165 in alleviating symptoms of irritable bowel syndrome(IBS): A randomized, placebo-controlled study. Nutrients 2020;12:1159. [doi: 10.3390/nu12041159].
02
Results
Overall evidence quality grade
0%

This probiotic has low to moderate quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0165 in alleviating symptoms of irritable bowel syndrome(IBS): A randomized, placebo-controlled study

    • 2020
    • Lewis ED, Antony JM, Crowley DC, et al.

    • Nutrients 2020;12:1159

    • DOI: 10.3390/nu12041159
    • 10 billion CFU
    • 8 weeks
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • PARALLEL-GROUP

    • ADULTS

    • ITT, PP (total) n=285,251
      ITT,PP (L. paracasei) n=95,84
      ITT,PP (B. longum) n= 95,86
      ITT,PP (placebo) n=95,81
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • No data

    • Constipation

      • No data

    • Bowel Habits

      • No data

    • Global IBS Symptoms

      • There were no significant changes between the groups; however, all three groups showed significant reductions in IBS-SSS (Irritable Bowel Syndrome Symptom Severity Score) at weeks 4 and 8 from baseline.

      • At week 4, IBS-SSS scores significantly decreased in participants supplemented with L. paracasei (−20%), B. longum (−20%), and placebo (−17%) (all p < 0.001).

      • Similarly, at week 8, IBS-SSS scores were significantly reduced in the L. paracasei (−30%), B. longum (−22%), and placebo (−31%) groups (all p < 0.001).

    • Abdominal Pain / Discomfort

      • No data

    • Bloating / Distention

      • No data

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • There were no significant within-group differences in HADS (Hospital Anxiety and Depression Scale) scores.

      • Additionally, there were no significant between-group differences among the three groups in the SF-36 (Short Form Health Survey) parameters assessed.

    • Quality of Life

      • L. paracasei supplementation improved quality of life in terms of emotional well-being (Cohen’s d = 0.23) and social functioning (Cohen’s d = 1.36) compared with baseline (p < 0.05). The mean effect size for all quality of life parameters assessed was 0.53.

    • Miscellaneous Symptoms

      • No data

    • Notes

      • This study was disqualified for the following reasons:

      • Poor Reporting Quality: The quality of reporting was atrocious, with results often presented only for subgroups by IBS type, and many results were only shown through graphs where variability measures were illegible due to overlapping lines.

      • Result Spinning: There was significant spinning of the results, undermining the credibility of the findings.

      • Conflict of Interest: The producer of the probiotic was involved in revising the manuscript text, raising concerns about impartiality.

      • Inconsistent Data: The number of participants completing the treatment differed in two places within the paper, indicating inconsistencies in the reported data.